Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471641 | 0.94 | LMNA (0.66) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL5468786 | 0.87 | ALDH1A1 (0.71) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL8752412 | 0.85 | L3MBTL1 (1.00) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL8752473 | 0.85 | HPGD (0.81) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL13265867 | 0.84 | ALDH1A1 (0.60) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL13265815 | 0.83 | AMY1A (0.54) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL3380247 | 0.83 | POLB (0.68) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL13728356 | 0.82 | CYP19A1 (0.54) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL20578066 | 0.82 | LMNA (0.73) | HPGDL3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL20578208 | 0.82 | LMNA (0.85) | HPGDL3MBTL1ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634948-B1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | INST NAT SANTE RECH MED (FR) | 2025-09-17 | — | — | EP | disclosed |
| EP-3634949-B1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INST NAT SANTE RECH MED (FR) | 2025-03-19 | — | — | EP | disclosed |
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| US-11607419-B2 | Inhibitors of RAC1 and uses thereof for inducing bronchodilatation | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-03-21 | — | — | US | disclosed |
| WO-2018224563-A9 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-22 | — | — | WO | disclosed |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | NANTES UNIVERSITE (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | NANTES UNIVERSITE (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-3634949-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2020-04-15 | — | — | EP | disclosed |
| EP-3634948-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018224563-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-13 | — | — | WO | disclosed |
| EP-3412651-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-12 | — | — | EP | disclosed |
| EP-3412652-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | RAC1, KRAS, CYRIB | HPGD 1309/4885L3MBTL1 1887/4885ALDH1A1 2069/4885 |
| US-11607419-B2 | Inhibitors of RAC1 and uses thereof for inducing bronchodilatation | RAC1, CYRIB, ARHGDIB | HPGD 550/4885L3MBTL1 3400/4885ALDH1A1 2264/4885 |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | RAC1, CYRIB, ARHGDIB | HPGD 550/4885L3MBTL1 3400/4885ALDH1A1 2264/4885 |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | HPGD 3767/4885L3MBTL1 583/4885ALDH1A1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.